Justin McAnear
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Justin McAnear
Earlier roles on record: CFO at 10x Genomics, Inc. (TXG) until August 30, 2024. 10x Genomics, Inc. reported in an 8-K filed August 8, 2024 that Justin McAnear resigned as Chief Financial Officer, effective August 30, 2024. The proxy statement of 10x Genomics, Inc. reports total compensation of $3,037,877 for Justin McAnear in fiscal 2024, including a base salary of $311,795. Disclosed compensation is on record for 7 fiscal years. Justin McAnear has spoken on 18 earnings calls across 1 company, most recently for 10x Genomics, Inc. on August 8, 2024.
“Justin McAnear, Chief Financial Officer, will resign from the company, effective August 30, to join a private company.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Start not stated–2024-08-30
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | 10x Genomics, Inc. (TXG) | Former Chief Financial Officer | $311,795 | $3,037,877 |
| 2023 | 10x Genomics, Inc. (TXG) | Former Chief Financial Officer | $413,963 | $3,306,950 |
| 2022 | 10x Genomics, Inc. (TXG) | Former Chief Financial Officer | $394,250 | $6,842,330 |
| 2021 | 10x Genomics, Inc. (TXG) | Chief Financial Officer | $367,500 | $4,457,553 |
| 2020 | 10x Genomics, Inc. (TXG) | Chief Financial Officer | $330,000 | $4,263,816 |
| 2019 | 10x Genomics, Inc. (TXG) | Chief Financial Officer | $325,000 | $648,311 |
| 2018 | 10x Genomics, Inc. (TXG) | Chief Financial Officer | $71,737 | $1,526,855 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.